Immutep operates as a biotechnology firm with a global presence, and it is publicly traded on the Australian Stock Exchange as well as the NASDAQ Global Market in the United States. Specializing in personalized bio-therapeutic products for cancer, Immutep is committed to utilizing its existing technology and knowledge to create novel treatment options for patients and enhance shareholder value. The primary product pipeline of Immutep is centered around the LAG-3 immune regulatory pathway, which plays a crucial role in controlling the T cell immune response. Its most advanced product in clinical development is an APC activator, functioning as a T cell immunostimulatory factor.